Androgens may regulate the male skeleton directly through a stimulation of androgen receptors or indirectly through aromatization of androgens into estrogen and, thereafter, through stimulation of estrogen receptors (ERs). The relative importance of ER subtypes in the regulation of the male skeleton was studied in ER␣-knockout (ERKO), ER-knockout (BERKO), and double ER␣͞-knockout (DERKO) mice. ERKO and DERKO, but not BERKO, demonstrated decreased longitudinal as well as radial skeletal growth associated with decreased serum levels of insulin-like growth factor I. Therefore, ER␣, but not ER, mediates important effects of estrogen in the skeleton of male mice during growth and maturation.
TRACP is synthesized as a latent proenzyme requiring proteolytic processing to attain maximal phosphatase activity. Excision of an exposed loop domain abolishes the interaction between the loop residue Asp146 and a ligand to the redox-sensitive iron of the active site, most likely Asn91, providing a mechanism for the enzyme repression. Both cathepsin K and L efficiently cleave in the loop domain and activate the latent enzyme, and we propose that cathepsin K acts as a physiological activator of TRACP in osteoclasts, whereas cathepsin L might fulfill a similar role in different types of macrophages. Considering the rather broad substrate specificity of TRACP, a tight regulation of its activity in the cell appears warranted. Besides proteolytic cleavage, the enzyme should need a specific local environment with a slightly acidic pH and reducing equivalents to keep the enzyme fully active. Cellular subcompartments where these required conditions prevail are potential subcellular site ( M AMMALIAN TARTRATE-RESISTANT purple acid phosphatase (TRACP/PAP) is an iron-containing, cationic glycoprotein with a molecular weight of around 35 kDa. Although the enzyme is translated as a single polypeptide, the protein isolated from different tissues commonly exist as a disulfide-linked two-subunit structure with an N-terminal fragment of 20 -23 kDa joined to the 16-to 17-kDa C-terminal part.(1) It now appears clear that the two-subunit form is generated by proteolytic excision of a loop domain protruding between helix 5 and 6 at the surface of the molecule, and that its removal leads to a significant increase in the enzymatic activity of the molecule at pH Ͼ5. Besides serine proteases (e.g., trypsin and chymotrypsin), several cysteine proteinases of the cathepsin family have been shown to cleave in the loop region, with the latter proteases leading to markedly higher enzyme activation. (3,4) We have focused our interest on the cysteine proteinases as potential physiological regulators of TRACP enzyme activation in osteoclasts and macrophages, primarily because members of this family have been implicated in resorption of bone as well as in lysosomal protein degradation. Interestingly, both cathepsin K and L are highly efficient activators of the latent monomeric TRACP in vitro.(5,6) Cathepsins B, H, and S were much less effective, and MMP 2 and 9 were completely ineffective.(5) Of the two cathepsins, only cathepsin K is expressed to a significant extent in osteoclasts, while cathepsin L predominate in other types of macrophages.(7) That cathepsin K is involved in processing of TRACP in bone was shown by use of cathepsin K knockout mice, where an increased content of monomeric TRACP was recovered from their bones.(5) Thus, members of the cathepsin family can process TRACP to a more active enzyme, and we propose that cathepsin K fulfills this role in osteoclasts while in other TRACP expressing cells of the macrophage lineage cleavage can be accomplished by cathepsin L.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.